EE192 The Cost-Effectiveness of a Bimekizumab Versus Secukinumab Treatment Pathway in Patients with Active Axial Spondyloarthritis in Scotland
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.461
https://www.valueinhealthjournal.com/article/S1098-3015(23)03591-X/fulltext
Title :
EE192 The Cost-Effectiveness of a Bimekizumab Versus Secukinumab Treatment Pathway in Patients with Active Axial Spondyloarthritis in Scotland
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03591-X&doi=10.1016/j.jval.2023.09.461
First page :
Section Title :
Open access? :
No
Section Order :
12489